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Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by
clinical cystic fibrosis isolates of Pseudomonas aeruginosa
Abstract
OBJECTIVES: The cephalosporin nitric oxide (NO)-donor prodrug DEA-C3D ('DiEthylAminCephalosporin-3'-Diazeniumdiolate') has been shown to initiate the dispersal of biofilms formed by the
Pseudomonas aeruginosa laboratory strain PAO1. In this study, we investigated whether DEA-C3D
disperses biofilms formed by clinical cystic fibrosis (CF) isolates of P. aeruginosa and its effect in
combination with two antipseudomonal antibiotics, tobramycin and colistin, in vitro. METHODS: βLactamase-triggered release of NO from DEA-C3D was confirmed using a gas-phase chemiluminescence
detector. MICs for P. aeruginosa clinical isolates were determined using the broth microdilution method. A
crystal violet staining technique and confocal laser scanning microscopy were used to evaluate the
effects of DEA-C3D on P. aeruginosa biofilms alone and in combination with tobramycin and colistin.
RESULTS: DEA-C3D was confirmed to selectively release NO in response to contact with bacterial βlactamase. Despite lacking direct, cephalosporin/β-lactam-based antibacterial activity, DEA-C3D was able
to disperse biofilms formed by three P. aeruginosa clinical isolates. Confocal microscopy revealed that
DEA-C3D in combination with tobramycin produces similar reductions in biofilm to DEA-C3D alone,
whereas the combination with colistin causes near complete eradication of P. aeruginosa biofilms in vitro.
CONCLUSIONS: DEA-C3D is effective in dispersing biofilms formed by multiple clinical isolates of P.
aeruginosa and could hold promise as a new adjunctive therapy to patients with CF.
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Objectives: The cephalosporin nitric oxide (NO)-donor prodrug DEA-C3D (‘DiEthylAmin-Cephalosporin-30 Diazeniumdiolate’) has been shown to initiate the dispersal of biofilms formed by the Pseudomonas aeruginosa
laboratory strain PAO1. In this study, we investigated whether DEA-C3D disperses biofilms formed by clinical cystic fibrosis (CF) isolates of P. aeruginosa and its effect in combination with two antipseudomonal antibiotics,
tobramycin and colistin, in vitro.
Methods: b-Lactamase-triggered release of NO from DEA-C3D was confirmed using a gas-phase chemiluminescence detector. MICs for P. aeruginosa clinical isolates were determined using the broth microdilution method.
A crystal violet staining technique and confocal laser scanning microscopy were used to evaluate the effects of
DEA-C3D on P. aeruginosa biofilms alone and in combination with tobramycin and colistin.
Results: DEA-C3D was confirmed to selectively release NO in response to contact with bacterial b-lactamase.
Despite lacking direct, cephalosporin/b-lactam-based antibacterial activity, DEA-C3D was able to disperse biofilms formed by three P. aeruginosa clinical isolates. Confocal microscopy revealed that DEA-C3D in combination
with tobramycin produces similar reductions in biofilm to DEA-C3D alone, whereas the combination with colistin
causes near complete eradication of P. aeruginosa biofilms in vitro.
Conclusions: DEA-C3D is effective in dispersing biofilms formed by multiple clinical isolates of P. aeruginosa and
could hold promise as a new adjunctive therapy to patients with CF.

Introduction
Pseudomonas aeruginosa, a ubiquitous Gram-negative opportunistic pathogen, is a major cause of morbidity and mortality in
cystic fibrosis (CF). Although initial P. aeruginosa lung infection
can often be eradicated, reinfection is common and the prevalence of chronic infection increases with age.1 Chronic lung infection is associated with the formation of biofilms, which, once
established, are almost impossible to eradicate despite aggressive antibiotic treatment.2

Biofilms in the CF lung typically develop as aggregated communities of bacteria in a self-produced exopolysaccharide matrix
that contains both bacterial and mammalian cell debris.3 Biofilms
are highly tolerant towards the host immune system and are up to
1000 times more tolerant to antibiotic treatment than when in
planktonic phases of growth. This increased tolerance to antimicrobials is multifactorial and arises from inactivation of antibiotics
in the biofilm matrix by bacterial secreted products or matrix components, the formation of unfavourable pH and oxygen gradients
within the biofilm that reduce antibiotic efficacy, and altered
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V

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

117

Downloaded from https://academic.oup.com/jac/article-abstract/75/1/117/5571146 by University of Wollongong Library user on 17 January 2020

Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses
biofilms formed by clinical cystic fibrosis isolates of
Pseudomonas aeruginosa

Soren et al.

Materials and methods
Bacterial strains and growth conditions
Bacterial strains used were P. aeruginosa PAO1 (University of Washington,
USA) and three clinical isolates of P. aeruginosa, PA21, PA30 and PA68, isolated from the sputum of CF patients based at University Hospital
Southampton NHS Foundation Trust (NHS Research Ethics Committee
08/H0502/126; patients aged 18, 19 and 51 years, respectively). PA21 and
PA68 were from patients with chronic P. aeruginosa infection whilst PA30
was from a patient with intermittent P. aeruginosa infection; all three clinical isolates were from patients during a period of CF exacerbation. Overnight
cultures were grown in LB broth at 37 C with agitation at 180 rpm. Biofilm
cultures were cultivated at 37 C in M9 minimal medium (pH 7; Formedium)
containing 48 mM Na2HPO4, 22 mM KH2PO4, 9 mM NaCl and 19 mM NH4Cl,
and supplemented with 2 mM MgSO4, 100 lM CaCl2 and 20 mM glucose
(all Sigma–Aldrich), with agitation at 50 rpm.

118

DEA-C3D and antibiotics
DEA-C3D potassium salt and DEA-C3D free carboxylic acid were synthesized at the University of Wollongong, Australia, and stored at #80 C with
desiccant. Details of synthesis for both DEA-C3D forms are described elsewhere.11,12 Stock solutions of DEA-C3D at 25.6 mM were prepared fresh in
DMAO (Sigma–Aldrich) and diluted in medium immediately prior to use.
Stock solutions of tobramycin and colistin sulfate (Sigma–Aldrich) were prepared in water at 20 mg/L and refrigerated or kept frozen until use.

Evaluation of NO release
The release of NO from DEA-C3D was assessed using a highly sensitive
chemiluminescence detector (CLD 88Y, Eco Physics), as previously
described.15 Briefly, the set-up consists of a glass reaction vessel that is
purged with a constant stream of carrier gas (300 mL/min) through a glass
frit and connected to a scrubbing bottle containing 1 M NaOH to trap acid
fumes and higher nitrogen oxides. NO generated in the reaction solution is
continuously purged from the solution and transferred to the reaction
chamber of the CLD where it reacts with ozone (O3). This reaction (see
equations below) generates nitrogen dioxide in an excited state (NO2*),
which emits light upon returning to the ground state.
NO þ O3 ! NO2  þ O2

(1)

NO2  ! NO2 þ hm ðlightÞ

(2)

The light is then quantified by a photomultiplier tube and used to calculate
the NO concentration. PBS was added to the reaction vessel (maintained at
37 C) while being continuously purged with air, and the baseline signal was
recorded (<5 ppb NO). Medical-grade air (BOC) was used as a purge/carrier
gas as all of the biological assays were carried out under aerobic conditions.
DEA-C3D stocks in DMSO were prepared fresh, diluted with PBS and added
to the reaction vessel to a final concentration of 10 lM, and Bacillus cereus
penicillinase (Sigma–Aldrich; 20 U) was then added. NO readings were
recorded using a PowerChrom data acquisition system (eDAQ), with each
run being carried out in duplicate. For quantification of NO release over
time, the area under the curve was integrated and concentrations
extracted from an NO calibration curve, where known concentrations of NO
were generated by nitrite reduction using the tri-iodide reagent, as previously described.15

Planktonic susceptibility to DEA-C3D potassium salt,
DEA-C3D carboxylic acid and cefaloram
The MICs of DEA-C3D potassium salt, DEA-C3D carboxylic acid and cefaloram for the planktonic cultures of four strains of P. aeruginosa were determined using the broth microdilution method. Briefly, a stock solution of the
agent was added to LB broth and 2-fold serial dilutions created in a 96-well
microtitre plate. After addition of a log phase inoculum in LB broth between
1%105 and 5%105 cfu/mL, plates were incubated at 37 C for 24 h. The MIC
was identified as the lowest concentration required to inhibit bacterial
growth, as determined by visual analysis.

Microtitre plate assays to investigate effects of DEAC3D potassium salt on clinical CF isolate biofilms of
P. aeruginosa
The effects of DEA-C3D potassium salt on biofilms formed by clinical isolates
of P. aeruginosa and PAO1 were analysed using the reported microtitre
plate-based assay with some modifications.16,17 Overnight cultures were
diluted 1 in 100 into freshly prepared M9 minimal medium and added into
the non-perimeter wells of a flat-bottomed tissue culture-treated 96-well
microtitre plate (Thermo Scientific). Perimeter wells were not utilized for biofilm growth as they represent the wells with the highest variability in biofilm
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bacterial cell metabolism.4–6 Persistent P. aeruginosa infection
results in the gradual destruction of lung tissue, progressive respiratory failure and premature death in the majority of CF
patients.7
A putative anti-biofilm treatment strategy involves reducing the
tolerance of P. aeruginosa cells to antibiotics by initiating their dispersal from the biofilm. Previous research has shown that low-dose nitric oxide (NO; 450 nM) causes the dispersal of P. aeruginosa
biofilms, rendering cells more susceptible to antimicrobials.8 NOinduced dispersal is caused by a reduction in the intracellular level of
the bacterial messenger molecule bis-(30 -50 )-cyclic dimeric guanosine monophosphate (c-di-GMP) through modulation of phosphodiesterase and diguanylate cyclase activities.9 A recent proof-ofconcept clinical trial conducted by our group demonstrated that
low-dose inhaled NO (10 ppm) as an adjunctive to antibiotic therapy
reduces P. aeruginosa burden in the lungs of CF patients without adverse effects,10 although pseudomonal biofilms were re-established
following cessation of treatment. NO gas delivery to individuals with
CF is expensive and impractical for routine care. A drug formulation
capable of delivering controlled low-dose NO to the biofilm is potentially a more practical way of achieving long-term benefits.
Cephalosporin-30 -diazeniumdiolates (C3Ds) are a recent class of
NO-donor prodrugs designed to locally release NO following reaction of their b-lactam moiety with bacterial b-lactamases, thus triggering biofilm dispersion. Targeted release of NO at chronic infection
sites by C3Ds could maximize NO delivery at the biofilm whilst minimizing host exposure to the reactive and potentially toxic NO. The
prototypical example DEA-C3D (‘DiEthylAmin-Cephalosporin-3’Diazeniumdiolate’) (Figure 1) contained the phenacetyl side chain of
the first-generation cephalosporin cefaloram and the diazeniumdiolate NO donor DEA/NO (t1=2=2 min).11,12 The proposed mechanism of
b-lactamase-triggered NO release and biofilm dispersion by DEAC3D is shown in Figure 1. A related analogue, PYRRO-C3D, consisting
of cefaloram linked to the faster acting diazeniumdiolate PYRRO/NO
(t1=2=2 s), was recently shown to have activity against Haemophilus
influenzae and Streptococcus pneumoniae biofilms.13,14
In our original reports on C3Ds, DEA-C3D was shown to disperse
biofilms of P. aeruginosa PAO1, a common laboratory biofilm
model.11,12 In this study, we investigated the ability of DEA-C3D
to disperse biofilms formed by clinical CF isolates of P. aeruginosa and
the anti-biofilm effects of its use in combination with the standardof-care antipseudomonal antibiotics tobramycin and colistin.
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Figure 1. Chemical structures. (a) Structure of the first-generation cephalosporin antibiotic cefaloram. (b) Structure of DEA-C3D (free acid and potassium salt forms) and NO release mechanism following reaction with b-lactamases (b-Lac). This figure appears in colour in the online version of JAC
and in black and white in the print version of JAC.
growth rate. Uninoculated M9 minimal medium was added to the perimeter wells and these served as negative controls. Plates were then incubated with shaking at 50 rpm at 37 C for 24 h. Following incubation, the
planktonic suspensions were gently aspirated using a pipette and the biofilms washed once with M9 minimal medium. Biofilms were then treated
with DEA-C3D, as follows: a stock concentration of DEA-C3D in DMSO
(25.6 mM) was diluted 1 in 100 in M9 minimal medium, to produce a final
concentration of 256 lM DEA-C3D with 1% DMSO. This was then serially
diluted in a new 96-well microtitre plate with M9 minimal medium containing 1% DMSO in a 2-fold manner (to maintain a consistent DMSO concentration across all DEA-C3D dilutions). Serial dilutions of DEA-C3D were then
added to the washed biofilm cultures. M9 minimal medium containing only
1% DMSO was added to the wells of the untreated control biofilms.
Following a 20 h treatment period, the planktonic suspensions were transferred to a new 96-well microtitre plate and the absorbance values were
recorded at 584 nm with a FLUOstar Omega plate reader (BMG Labtech) to
assess viability of the planktonic cultures. Biofilms were then washed twice
with PBS, stained with 0.1% crystal violet for 15 min and then washed once
more to remove excess stain. To extract the crystal violet back into solution,
30% acetic acid was added to the wells and left for 20 min at room temperature. The absorbance of the resolubilized crystal violet stain was then
measured at 584 nm with the FLUOstar Omega plate reader (BMG Labtech).

Microscopy of biofilms treated with DEA-C3D potassium
salt and antibiotics
Confocal laser scanning microscopy (CLSM) was used to analyse the effects
of DEA-C3D and antibiotics on P. aeruginosa strain PA68 biofilms. Overnight
cultures were diluted 1 in 100 in M9 minimal medium and inoculated into
35 mm glass bottom microwell plates (MatTek Corporation). Plates were
incubated at 37 C with gentle shaking at 50 rpm for 24 h and then treated
with DEA-C3D and/or antibiotics for 20 h. Antibiotic concentrations were
chosen based on preliminary experiments to establish concentrations that
were sublethal to the biofilm. Following treatment, biofilms were washed
twice with Hanks balanced salt solution to remove non-attached cells, and
biofilm viability was assessed using the LIVE/DEAD BacLight Bacterial
Viability Kit (Life Technologies) containing dyes SYTO9 and propidium iodide
(PI), as per the manufacturer’s instructions. Biofilms were then examined
with an inverted Leica SP8 confocal laser scanning microscope using the
%63 oil immersion lens with scanning at 1 lm intervals. Argon and DPSS
laser lines at 488 nm and 561 nm were used for excitation and the FITC filter set cube was used to acquire images. Images were obtained and analysed using the LAS AF software (Leica Microsystems GmbH). Assays were

performed using two technical replicates of two biological replicates (n=4);
five images were taken from each replicate biofilm, in a pre-determined
pattern to avoid selection bias. COMSTAT 2.0 software was used for quantitative analysis of images.18

Statistical analysis
GraphPad Prism 7.0 was used to conduct statistical analysis. Specific tests
are detailed in the figure captions. A P value of <0.05 was deemed significant. For all analyses: ns=non-significant, *=P < 0.05, **=P < 0.01,
***=P < 0.001 and ****=P < 0.0001.

Results
DEA-C3D selectively releases NO in response to
penicillinase
A highly sensitive chemiluminescence detection (CLD) method
was used to confirm b-lactamase-triggered release of NO from
DEA-C3D (Figure 2). The DEA-C3D potassium salt and carboxylic
free acid forms both exhibited a similar NO release profile, showing
minimal or no spontaneous release of NO in buffer alone and profound NO release within 1 min following addition of penicillinase.
Peak NO release rates occurred at 5 min, after which both compounds displayed a gradual decline in NO levels over time. Total
amounts of NO released from each compound (in moles) were calculated by comparing with peak areas of NO generated from sodium nitrite standards injected into a reducing reaction solution.
Per 1 mL of a 10 lM solution (10 nmol), DEA-C3D carboxylic acid
produced an average of 3.92 nmol of NO, whilst DEA-C3D potassium salt produced almost twice as much (an average of 6.82
nmol). This corresponded to an approximate NO yield of 40% and
70%, respectively, within 30 min.

DEA-C3D lacks direct antibacterial activity against
P. aeruginosa
MIC assays were carried out to measure the direct antibacterial activity of DEA-C3D potassium salt, DEA-C3D carboxylic free acid and
cefaloram. The compounds were tested against PAO1 and three
clinical CF isolates (PA21, PA30 and PA68). For all four P. aeruginosa
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strains there was no attainable MIC value for either DEA-C3D form,
with bacterial growth observed at all concentrations up to 128 lM.

200
DEA-C3D potassium salt
DEA-C3D carboxylic
free acid

Biofilms formed by multiple clinical CF isolates of
P. aeruginosa are dispersed by DEA-C3D

100

50
Cm Pn

W

0
0

10

20

30

Time (min)

Figure 2. Representative traces showing NO release from DEA-C3D (potassium salt and carboxylic acid) upon exposure to penicillinase. The release of NO was followed in real time by gas-phase chemiluminescence,
with concentrations expressed in parts per billion (ppb). Arrows denote
the time the compounds (Cm) and 20 U of B. cereus penicillinase (Pn)
were added to the reaction chamber. Readings were discontinued
30 min after addition of penicillinase, at which time the reaction chamber was washed (W) and prepared for the next analysis. Experiments
were carried out in duplicate and showed similar results.
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Crystal violet assays were used to evaluate the effects of DEA-C3D
potassium salt on biofilms formed by the laboratory strain PAO1
and three clinical CF isolates of P. aeruginosa (Figure 3). For
PAO1, DEA-C3D produced a dose-dependent reduction in biofilm
biomass. At the highest concentration (256 lM), the mean biofilm
biomass for PAO1 was reduced by 52% (P<0.0001) compared with
untreated controls. DEA-C3D also dispersed biofilms formed by all
three CF isolates in a dose-dependent manner, although the extent of dispersal was strain dependent. At the highest concentration (256 lM), DEA-C3D reduced the biofilm biomass of PA21, PA30
and PA68 by 41% (P<0.0001), 45% (P<0.0001) and 15%
(P<0.0001), respectively, compared with the untreated controls for
each isolate. Increased turbidity of the respective planktonic suspensions confirmed that DEA-C3D was causing biofilm dispersal, as
opposed to exerting a direct antibacterial effect (see Figure S1,
available as Supplementary data at JAC Online).
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Figure 3. Dispersal of P. aeruginosa biofilms by DEA-C3D potassium salt. (a) PAO1 and three clinical CF isolates of P. aeruginosa: (b) PA21; (c) PA30;
and (d) PA68. Biofilms were treated with DEA-C3D potassium salt before staining with crystal violet and extraction into acetic acid for spectrophotometric quantification. Results represent the mean±SEM from two independent experiments, each with six technical replicates (n=12). Ordinary oneway ANOVA with Dunnett’s multiple comparisons test was used for statistical analyses and each treatment group was compared with the untreated
control. Values were normalized to 100 according to the untreated control for each isolate.
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Figure 4. Appearance of P. aeruginosa biofilms following tobramycin and DEA-C3D treatments, alone and in combination. Biofilms formed by P. aeruginosa clinical CF isolate PA68 were treated with 4 mg/L tobramycin (b), 256 lM DEA-C3D potassium salt (c) or DEA-C3D/tobramycin combination (d),
and compared with untreated control biofilms (a). Biofilms were stained with SYTO9 (green=viable cells) and propidium iodide (red=dead/damaged
cells) before CLSM. Representative 3D images of each treatment are shown; x- and y-axes=246 lm by 246 lm. Experiments were carried out in duplicate and showed similar results.

DEA-C3D reduces biofilm biomass, thickness and surface
area coverage of biofilms formed by P. aeruginosa
clinical CF isolate PA68 alone and in combination with
tobramycin
CLSM was used to further probe the effects of DEA-C3D potassium
salt on P. aeruginosa biofilms and to investigate the effects of cotreatment with tobramycin. Clinical isolate PA68 was chosen for
these assays as it demonstrated robust and reproducible biofilm
growth in vitro. Treatment with DEA-C3D (256 lM) visibly reduced
the amount of biofilm formed by PA68 compared with untreated
controls (Figure 4). Treatment with tobramycin alone (4 mg/L)
showed no apparent effect, whereas co-treatment with DEA-C3D
and tobramycin reduced the biofilm to a similar extent to DEA-C3D
alone.
Quantifiable biofilm parameters supported the visual findings.
DEA-C3D-treated biofilms showed a statistically significant reduction in total biofilm biomass, biofilm thickness distribution and total
biofilm surface area coverage compared with untreated controls
(Figure 5). Biofilms treated with tobramycin showed no effect in all
three markers, whereas the combination of DEA-C3D and tobramycin produced statistically significant reductions compared with
the untreated controls.

The mean total biofilm biomass was reduced by 50.2% by DEAC3D (P=0.0069) and by 65.1% by the DEA-C3D/tobramycin
(P=0.0006) combination compared with the untreated controls,
though there was no significant difference between these two
treatment groups (P=0.4122). Compared with tobramycin-treated
biofilms, the combination treatment produced a 57.3% reduction
in mean biofilm biomass (P=0.0453), though mean thickness distribution and surface area coverage did not demonstrate a significant change (P=0.2471 and P=0.0550, respectively). There was no
statistically significant difference for any of the quantifiable
parameters between biofilms treated with DEA-C3D alone or the
DEA-C3D/tobramycin combination.

DEA-C3D in combination with colistin results in
almost complete eradication of biofilms formed by
P. aeruginosa clinical CF isolate PA68
CLSM was used to investigate the anti-biofilm effects of DEA-C3D
potassium salt in combination with colistin. Treatment of biofilms
with colistin alone produced a visible effect, reducing both the
amount of biofilm present and the number of viable
cells. However, large ‘microcolonies’ consisting mostly of live
P. aeruginosa cells still remained (Figure 6). DEA-C3D alone
121
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Chronic P. aeruginosa biofilm infection in the CF lung is associated
with worsening respiratory status, and current antibiotic therapies
are ineffective; our study has shown that the NO-releasing cephalosporin prodrug DEA-C3D is effective at dispersing such biofilms
in vitro.
Previous studies with DEA-C3D had demonstrated its ability to
disperse biofilms formed by the P. aeruginosa laboratory strain
PAO1.11,12 In these studies, clinical P. aeruginosa strains were not
examined and biofilms were only grown for 6 h. During the early
stages of biofilm formation, planktonic cells attach to a substratum, first reversibly and then irreversibly. Cells then begin to produce a self-encasing extracellular matrix and, at later stages of
biofilm maturity, microcolony structures.19 A 6 h incubation period
is likely to recapitulate only the very early stages of biofilm formation. In this study, biofilms were cultured for a total of 44 h and are
thus more representative of mature biofilms. Established biofilms
are more difficult to eradicate than nascent biofilms and are likely
to better represent chronic P. aeruginosa infection in vivo.20
Before performing the biofilm experiments, a highly sensitive
chemiluminescence method was used to confirm release of NO
from two variants of DEA-C3D, i.e. the potassium salt and free carboxylic acid forms, following exposure to a commercial b-lactamase (B. cereus penicillinase). We noted that the DEA-C3D
potassium salt released almost double the amount of NO compared with the free acid. The reasons for the difference are not
clear as both forms would be present in the buffered aqueous solution after equilibration. Differences in aqueous solubility may be a
factor, where the potassium salt would be expected to be more
soluble.21 The importance of this observation for potential clinical
applications of C3Ds will require further investigation. Due to its
greater propensity to generate NO under in vitro experimental conditions, the DEA-C3D potassium salt form was selected for use in
the biofilm experiments.
Biofilms formed by clinical isolates taken from adolescent and
adult CF patients with chronic P. aeruginosa respiratory infections
were dispersed by DEA-C3D but the reductions in biofilm biomass
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Figure 5. DEA-C3D potassium salt causes a reduction in P. aeruginosa
clinical CF isolate PA68 biofilms alone and in combination with tobramycin. (a) Total biofilm biomass, representing live and dead biomass
combined. (b) Biofilm thickness distribution. (c) Total biofilm surface area
coverage. Values for all parameters were obtained from COMSTAT analysis of CLSM images. Scatter plots show all data points from n=4, with
the mean and SD. One-way ANOVA with Tukey’s multiple comparisons
tests were used for statistical analyses. TOB, tobramycin.

appeared to cause a visible reduction, but the effect of the combination treatment was much more striking, with virtually no viable
cells remaining and almost all of the biofilm removed from the
substratum. These observations were seen consistently across replicates; see the Supplementary data for the maximum projection
images (cumulative z stacks) of all replicate images for untreated
122

control biofilms (Figure S2), DEA-C3D-treated biofilms (Figure S3),
colistin-treated biofilms (Figure S4) and DEA-C3D/colistin-treated
biofilms (Figure S5).
The quantifiable biofilm parameters supported the visual observations. DEA-C3D-treated biofilms caused statistically significant
reductions in total biofilm biomass, maximum biofilm thickness
and total biofilm surface area coverage compared with untreated
controls (Figure 7). The mean of all three parameters was significantly reduced in biofilms treated with the DEA-C3D/colistin combination compared with both untreated control biofilms and
biofilms treated with DEA-C3D only. Compared with the untreated
controls, the mean total biofilm biomass was reduced by 50.9%
with DEA-C3D treatment (P=0.0036), by 89.8% with colistin treatment (P<0.0001) and by 97.8% with the DEA-C3D/colistin combination treatment (P<0.0001). There was no statistically significant
difference in mean biofilm biomass or mean surface area coverage
between colistin treatment alone and treatment with the
DEA-C3D/colistin combination, though there was a statistically significant change in mean maximum biofilm thickness (51.5% reduction, P=0.0193).
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Figure 6. DEA-C3D enhances the activity of colistin against P. aeruginosa biofilms. Biofilms formed by clinical CF isolate PA68 were treated with
16 mg/L colistin (b), 256 lM DEA-C3D potassium salt (c) or DEA-C3D/colistin combination (d), and stained with SYTO9 (green=viable cells) and propidium iodide (red=dead/damaged cells) before imaging by CLSM. Untreated control biofilms are shown in (a). Representative 3D images for each treatment are shown; x- and y-axes=246 lm by 246 lm. Experiments were carried out in duplicate and showed similar results.

varied between isolates. At the highest concentration tested, PAO1
biofilms showed a 52% reduction in biomass following treatment,
while the clinical isolates displayed reductions between 15% and
45%. One possible explanation for this could be differing levels of
b-lactamase expression by each strain, leading to variations in NO
exposure. Although encoded for chromosomally, b-lactamase
AmpC is expressed at low basal levels in environmental strains.
Stable derepression leading to a higher expression of AmpC
commonly occurs in CF isolates.22,23 Another explanation is that
NO dispersal responses vary across strains due to differences in
the state of biofilm maturity. While all four P. aeruginosa
strains were cultured for 44 h, their rates of biofilm growth were
different. Further investigations are warranted to investigate these
theories.
The most commonly prescribed aminoglycoside antibiotic for
CF patients is tobramycin, which targets the ribosomal subunits of
Gram-negative pathogens to inhibit protein synthesis.24 Like most
antibiotics, tobramycin is only effective against actively dividing
cells and is less effective against cells within a biofilm. Using CLSM
and COMSTAT analysis, treatment of P. aeruginosa biofilms with
DEA-C3D alone verified the results obtained with crystal violet
assays, indicating dispersal of the biofilm. In contrast, treatment
with tobramycin alone showed no effect on biofilms, consistent
with findings from the literature.10,25 The combination of DEA-C3D

and tobramycin was an effective anti-biofilm treatment, reducing
the biofilm biomass over 2-fold more than tobramycin alone.
These data demonstrate that biofilm cells tolerant of tobramycinmediated killing are responsive to the NO dispersal signal.
However, there was no statistically significant difference in
the anti-biofilm effect of DEA-C3D treatment and treatment with
the DEA-C3D/tobramycin combination.
Colistin is an antibiotic that is often administered by inhalation
to treat P. aeruginosa infection in CF patients.26 Using CLSM, we
demonstrated that colistin treatment of P. aeruginosa biofilms had
affected the viability of a large proportion of the biofilm cells and
had reduced the mean biofilm biomass by 89.8% in comparison
with the untreated control. However, multiple dense aggregates
or microcolony-like structures containing dense clusters of live
cells were still present. Co-treatment with colistin and DEA-C3D
also showed an anti-biofilm effect, with a 97.8% reduction in
mean biofilm biomass in comparison with the untreated control.
However, quantitative analysis revealed that there was no significant difference in total biofilm biomass or surface area coverage
between the colistin-only and DEA-C3D/colistin treatments.
Interestingly, however, the mean maximum biofilm thickness
was reduced from 32 lm (untreated control biofilms) to 22 lm
with DEA-C3D treatment, to 14 lm with colistin treatment and
to <7 lm with the DEA-C3D/colistin combination. This reduction in
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biofilm thickness with the DEA-C3D/colistin combination treatment compared with the colistin-only treatment was statistically
significant. This can be attributed to the scarcity of the large clusters of live cells in the biofilms treated with the combination treatment, which were seen in abundance in the biofilms treated only
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with colistin. These microcolony structures likely represent a subpopulation of cells more tolerant to colistin attack and/or may be
classed as ‘persister’ cells. Persister cells often represent <1% of
the biofilm population, are more difficult to eradicate than the
other 99% and their presence can cause repopulation or regrowth
of a biofilm which is one of the known mechanisms of biofilm tolerance.27 Therefore, the reduced biofilm thickness and the reduced
number of large clusters of live cells with the DEA-C3D/colistin
combination indicates that this is a superior treatment to colistin
alone and may have an increased likelihood of preventing biofilm
regrowth following cessation of treatment. Further investigations
are required to support this theory.
In conclusion, we have demonstrated that DEA-C3D is an effective anti-biofilm against CF isolates of P. aeruginosa in vitro.
Though we could not confirm any synergistic activity of DEA-C3D in
combination with tobramycin or colistin, we observed evidence to
suggest that DEA-C3D in combination with colistin could prevent
biofilm regrowth. Current efforts in our labs are aiming to create
b-lactamase-stable C3Ds designed to release NO and disperse
P. aeruginosa biofilms following reactions with transpeptidases.
Such C3Ds are potentially dual-action anti-biofilm compounds
able to both kill bacteria and disperse biofilms, thus removing the
requirement for co-administered antibiotics.
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